282 related articles for article (PubMed ID: 21076522)
21. Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.
Liu Z; Noh HS; Chen J; Kim JH; Falo LD; You Z
J Immunol; 2008 Sep; 181(6):4363-70. PubMed ID: 18768895
[TBL] [Abstract][Full Text] [Related]
22. Endogenous T cells prevent tumor immune escape following adoptive T cell therapy.
Walsh SR; Simovic B; Chen L; Bastin D; Nguyen A; Stephenson K; Mandur TS; Bramson JL; Lichty BD; Wan Y
J Clin Invest; 2019 Dec; 129(12):5400-5410. PubMed ID: 31682239
[TBL] [Abstract][Full Text] [Related]
23. Improving T cell therapy for cancer.
Leen AM; Rooney CM; Foster AE
Annu Rev Immunol; 2007; 25():243-65. PubMed ID: 17129181
[TBL] [Abstract][Full Text] [Related]
24. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.
Beck BH; Kim HG; Kim H; Samuel S; Liu Z; Shrestha R; Haines H; Zinn K; Lopez RD
Breast Cancer Res Treat; 2010 Jul; 122(1):135-44. PubMed ID: 19763820
[TBL] [Abstract][Full Text] [Related]
25. Cancer immunotherapy: moving forward with peptide T cell vaccines.
Kumai T; Fan A; Harabuchi Y; Celis E
Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
[TBL] [Abstract][Full Text] [Related]
26. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
27. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
28. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
Kohli K; Yao L; Nowicki TS; Zhang S; Black RG; Schroeder BA; Farrar EA; Cao J; Sloan H; Stief D; Cranmer LD; Wagner MJ; Hawkins DS; Pillarisetty VG; Ribas A; Campbell J; Pierce RH; Kim EY; Jones RL; Riddell SR; Yee C; Pollack SM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963013
[TBL] [Abstract][Full Text] [Related]
29. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy.
Wang LX; Kjaergaard J; Cohen PA; Shu S; Plautz GE
J Immunol; 2004 Mar; 172(6):3462-8. PubMed ID: 15004146
[TBL] [Abstract][Full Text] [Related]
30. Adoptive immunotherapy for cancer: harnessing the T cell response.
Restifo NP; Dudley ME; Rosenberg SA
Nat Rev Immunol; 2012 Mar; 12(4):269-81. PubMed ID: 22437939
[TBL] [Abstract][Full Text] [Related]
31. Genome-wide fitness gene identification reveals Roquin as a potent suppressor of CD8 T cell expansion and anti-tumor immunity.
Zhao H; Liu Y; Wang L; Jin G; Zhao X; Xu J; Zhang G; Ma Y; Yin N; Peng M
Cell Rep; 2021 Dec; 37(10):110083. PubMed ID: 34879274
[TBL] [Abstract][Full Text] [Related]
32. Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy.
Innamarato P; Kodumudi K; Asby S; Schachner B; Hall M; Mackay A; Wiener D; Beatty M; Nagle L; Creelan BC; Sarnaik AA; Pilon-Thomas S
Mol Ther; 2020 Oct; 28(10):2252-2270. PubMed ID: 32615068
[TBL] [Abstract][Full Text] [Related]
33. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
[TBL] [Abstract][Full Text] [Related]
34. Cellular networks controlling T cell persistence in adoptive cell therapy.
Chan JD; Lai J; Slaney CY; Kallies A; Beavis PA; Darcy PK
Nat Rev Immunol; 2021 Dec; 21(12):769-784. PubMed ID: 33879873
[TBL] [Abstract][Full Text] [Related]
35. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies.
Tantalo DG; Oliver AJ; von Scheidt B; Harrison AJ; Mueller SN; Kershaw MH; Slaney CY
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035114
[TBL] [Abstract][Full Text] [Related]
36. T-cell death and cancer immune tolerance.
Lu B; Finn OJ
Cell Death Differ; 2008 Jan; 15(1):70-9. PubMed ID: 18007660
[TBL] [Abstract][Full Text] [Related]
37. Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy.
Yee C; Lizee GA
Cancer J; 2017; 23(2):144-148. PubMed ID: 28410303
[TBL] [Abstract][Full Text] [Related]
38. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
[TBL] [Abstract][Full Text] [Related]
39. Reverse immunoediting: When immunity is edited by antigen.
Merlo A; Dalla Santa S; Dolcetti R; Zanovello P; Rosato A
Immunol Lett; 2016 Jul; 175():16-20. PubMed ID: 27131431
[TBL] [Abstract][Full Text] [Related]
40. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
